OncRef

Clinical Trial: NCT02971501

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-08-13

Study Overview

Brief Summary

This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain (brain metastases). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop or slow non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. Giving osimertinib with or without bevacizumab may work better in treating patients with non-small cell lung cancer.

Official Title

A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases

Conditions

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8

Intervention / Treatment

  • Biological: Bevacizumab
  • Procedure: Biopsy Procedure
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Procedure: Magnetic Resonance Imaging
  • Drug: Osimertinib

Other Study ID Numbers

  • NCI-2016-01733
  • NCI-2016-01733
  • 2000021123
  • 10042
  • 10042
  • 10042
  • UM1CA186689

Start Date (Actual)

2018-06-27

Primary Completion Date (Actual)

2025-02-18

Study Completion Date (Estimated)

2027-07-01

Enrollment (Actual)

5

Study Type

Interventional

Phase

Phase 2